FDA Accepts Orexo's IND for Needle-Free Intranasal Epinephrine Powder OX640 in Anaphylaxis
核心洞察
The FDA has accepted Orexo's Investigational New Drug application for OX640, a nasally administered epinephrine powder for emergency treatment of anaphylaxis (搜索).
OX640 uses Orexo's AmorphOX (搜索) delivery platform and has shown rapid epinephrine absorption, robust pharmacokinetics, and good tolerability in completed clinical studies.
The candidate also demonstrated strong stability across a broad temperature range, potentially enabling longer shelf life than marketed and investigational products.
The U.S. Food and Drug Administration has accepted Orexo AB's Investigational New Drug (IND) application for OX640, a nasally administered powder formulation of epinephrine intended for the emergency treatment of anaphylaxis (搜索). The acceptance, announced by the Uppsala, Sweden-based company on September 14, 2026, clears the way for Orexo to initiate a pivotal clinical development program for the needle-free candidate.
OX640 is built on Orexo's proprietary drug delivery platform AmorphOX (搜索), which the company says enables formulation of medicines with improved stability and rapid absorption through the nasal mucosa. The product is designed to deliver epinephrine rapidly and reliably without injection, addressing what Orexo describes as important limitations of current autoinjectors, including needle fear, use errors, and challenges related to storage and shelf life.
Clinical and Stability Data Supporting the Filing
According to Orexo, the IND application is supported by extensive preclinical documentation as well as positive results from completed clinical studies. Those studies demonstrated rapid absorption of epinephrine, a robust pharmacokinetic profile, and good tolerability. The company also reported that OX640 has shown very strong stability properties across a broad temperature range, potentially enabling improved shelf life compared with other products on the market and in development.
"The IND submission for OX640 is an important milestone for Orexo and a significant step in the development of a new treatment option for patients at risk of anaphylaxis (搜索)," said Nikolaj Sørensen, President and CEO of Orexo. "Although epinephrine is well established as a treatment, significant challenges remain with today's injection-based products. With OX640, we have the opportunity to offer a needle-free, user-friendly, and temperature-stable product with the potential to improve treatment for patients worldwide."
Development Timeline and Partnering Efforts
Orexo said it plans to initiate the pivotal clinical development program during the fourth quarter of 2026. Based on current plans, the OX640 New Drug Application is expected to be ready in 2028 for regulatory submission.
The company is also continuing ongoing activities to identify a partner for the further development and commercialization of OX640. Orexo stated that, supported by the promising clinical results, strong stability data, and its proprietary AmorphOX (搜索) technology, it believes OX640 has the potential to become an attractive treatment option for patients at risk of severe allergic reactions.
Platform and Company Context
AmorphOX (搜索) is described by Orexo as a proprietary drug delivery technology that improves bioavailability and stability for both large and small molecules, enabling new approaches to administration, manufacturing, and distribution. OX640 is being developed specifically as a needle-free alternative to today's epinephrine autoinjectors.
Orexo is a Swedish pharmaceutical company focused on advancing treatments for severe diseases and life-saving rescue medications. The company reports more than 30 years of experience and multiple drugs approved globally, and is advancing a diversified pipeline of programs in clinical and preclinical development. It collaborates with partners in research, development, and commercialization, is headquartered in Uppsala, and is listed on Nasdaq Stockholm's main market and trades as ADRs on the OTCQX market in the United States.